Die Übersetzung dieser Seite ist experimentell und in Entwicklung. Wir freuen uns über Ihr !

Rafael Holdings Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 4/6

Rafael Holdings hat ein Gesamteigenkapital von $102.3M und eine Gesamtverschuldung von $1.7M, was einen Verschuldungsgrad von 1.7% ergibt. Die Gesamtaktiva und Gesamtpassiva betragen $106.1M bzw. $3.9M.

Wichtige Informationen

1.7%

Verhältnis von Schulden zu Eigenkapital

US$1.70m

Verschuldung

Zinsdeckungsgrad	n/a
Bargeld	US$7.14m
Eigenkapital	US$102.25m
Gesamtverbindlichkeiten	US$3.90m
Gesamtvermögen	US$106.15m

Jüngste Berichte zur Finanzlage

We Think Rafael Holdings (NYSE:RFL) Needs To Drive Business Growth Carefully

Aug 04

Is Rafael Holdings (NYSE:RFL) Using Debt In A Risky Way?

Jan 20

Recent updates

Rafael stepping back from early-stage development in favor of acquisition, licensing

Nov 16

Is Rafael Holdings (NYSE:RFL) Using Debt In A Risky Way?

Jan 20

Rafael Holdings: A Coin Flip

Nov 18

Rafael Holdings announces merger with Rafael Pharmaceuticals

Jun 21

Rafael Holdings adds three new members to board

Jun 14

What You Need To Know About Rafael Holdings, Inc.'s (NYSE:RFL) Investor Composition

Jan 25

Rafael Holdings reports FQ1 results

Dec 15

The Rafael Holdings (NYSE:RFL) Share Price Has Gained 29% And Shareholders Are Hoping For More

Dec 01

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: RFLDie kurzfristigen Aktiva des Unternehmens ($10.5M) übersteigen seine kurzfristigen Passiva ($3.3M).

Langfristige Verbindlichkeiten: RFLDie kurzfristigen Vermögenswerte des Unternehmens ($10.5M) übersteigen seine langfristigen Verbindlichkeiten ($632.0K).

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: RFL über mehr Barmittel verfügt als seine Gesamtverschuldung.

Schulden abbauen: RFL Das Verhältnis von Schulden zu Eigenkapital ist in den letzten 5 Jahren von 11.7% auf 1.7% zurückgegangen.

Schuldendeckung: RFLDer operative Cashflow des Unternehmens ist negativ, so dass die Schulden nicht ausreichend gedeckt sind.

Zinsdeckung: Es liegen nicht genügend Daten vor, um festzustellen, ob die Zinszahlungen von RFL auf seine Schulden durch EBIT gut gedeckt sind.

Rafael Holdings Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 4/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

We Think Rafael Holdings (NYSE:RFL) Needs To Drive Business Growth Carefully

Is Rafael Holdings (NYSE:RFL) Using Debt In A Risky Way?

Recent updates

Solid Earnings May Not Tell The Whole Story For Rafael Holdings (NYSE:RFL)

First half 2024 earnings released: EPS: US$0.10 (vs US$0.35 loss in 1H 2023)

Less than half of directors are independent

First quarter 2024 earnings released: US$0.15 loss per share (vs US$0.22 loss in 1Q 2023)

Rafael Holdings, Inc., Annual General Meeting, Jan 10, 2024

Full year 2023 earnings released: US$0.36 loss per share (vs US$6.21 loss in FY 2022)

Rafael Holdings, Inc. Announces Resignation of Rachel Jonas as Director

We Think Rafael Holdings (NYSE:RFL) Needs To Drive Business Growth Carefully

First half 2023 earnings released: US$0.35 loss per share (vs US$5.86 loss in 1H 2022)

Rafael Holdings, Inc. Announces Resignation of David Polinsky as Chief of Staff

First quarter 2023 earnings released: US$0.22 loss per share (vs US$5.88 loss in 1Q 2022)

Rafael Holdings GAAP EPS of -$0.22

Rafael Holdings, Inc., Annual General Meeting, Jan 23, 2023

Rafael stepping back from early-stage development in favor of acquisition, licensing

Founder & Chairman notifies of intention to sell stock

Rafael Holdings, Inc.(NYSE:RFL) dropped from Russell 2000 Dynamic Index

Third quarter 2022 earnings released: US$0.28 loss per share (vs US$0.15 loss in 3Q 2021)

Rafael Holdings, Inc. Announces Directorate Changes

Is Rafael Holdings (NYSE:RFL) Using Debt In A Risky Way?

Rafael Pharmaceuticals Announces Ongoing Successful Enrollment and Opening of Additional Sites for Phase 2 Clinical Trial of Cpi-613® (Devimistat) in Combination with Gemcitabine and Cisplatin in Patients with Biliary Tract Cancer

First quarter 2022 earnings: Revenues in line with analyst expectations

Rafael Holdings: A Coin Flip

Full year 2021 earnings released: US$1.49 loss per share (vs US$0.66 loss in FY 2020)

Rafael Holdings, Inc. announced that it has received $104.169835 million in funding from a group of investors

Rafael Holdings, Inc. announced that it expects to receive $104.16987 million in funding

Rafael Holdings, Inc.(NYSE:RFL) dropped from Russell Microcap Value Index

Rafael Holdings announces merger with Rafael Pharmaceuticals

Third quarter 2021 earnings released: US$0.15 loss per share (vs US$0.14 loss in 3Q 2020)

Rafael Holdings adds three new members to board

Second quarter 2021 earnings released

Rafael Holdings, Inc. Appoints Ameet Mallik as Chief Executive Officer, Effective May 1, 2021

New 90-day high: US$45.51

Rafael Holdings Names William Conkling as Chief Commercial Officer, Effective March 15, 2021

New 90-day high: US$28.00

What You Need To Know About Rafael Holdings, Inc.'s (NYSE:RFL) Investor Composition

New 90-day high: US$24.60

First quarter 2021 earnings released: US$0.091 loss per share

Rafael Holdings reports FQ1 results

New 90-day high: US$22.33

Rafael Pharmaceuticals Partners with Sara’s Cure and SARC for the Launch of Phase 2 Clinical Trial for CPI-613® (devimistat) in Combination with Hydroxychloroquine for Patients with Clear Cell Sarcoma of Soft

The Rafael Holdings (NYSE:RFL) Share Price Has Gained 29% And Shareholders Are Hoping For More

Rafael Holdings, Inc., Annual General Meeting, Jan 13, 2021

New 90-day high: US$21.65

Full year earnings released - US$0.66 loss per share

Rafael Holdings, Inc. to Report Q4, 2020 Results on Oct 29, 2020

New 90-day high - US$18.88

Analyse der Finanzlage

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Bilanz

Entdecken Sie finanziell stabile Unternehmen